New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 8, 2013
13:56 EDTUTHRUnited Therapeutics price target raised to $75 from $65 at Argus
Argus increased its price target on United Therapeutics after the company reported higher than expected Q4 EPS. The firm continues to believe that the company will generate strong long-term growth, and it maintains a Buy rating.
News For UTHR From The Last 14 Days
Check below for free stories on UTHR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 29, 2014
16:21 EDTUTHROn The Fly: Closing Wrap
Subscribe for More Information
13:05 EDTUTHRUnited Therapeutics price target raised to $141 from $133 at Wedbush
Subscribe for More Information
12:53 EDTUTHRCourt ruling in Remodulin patent case favors United Therapeutics
Subscribe for More Information
12:49 EDTUTHRStocks with increasing volume options volume
Stocks with increasing volume options volume: OXY HD RSH UTHR IRF TTWO CONN
12:18 EDTUTHROn The Fly: Midday Wrap
Subscribe for More Information
11:07 EDTUTHRHigh option volume stocks
Subscribe for More Information
10:51 EDTUTHRUnited Therapeutics jumps after court rules generic will infringe
United Therapeutics (UTHR) alleged patent infringement against Sandoz, a unit of Novartis (NVS), related to the latter's filing for approval of a generic version of United Therapeutics' remodulin drug. A New Jersey court ruled today that Sandoz's proposed ANDA product will infringe the claims of UTC's '117 patent, according to a court filing. Following the court ruling, shares of United Therapeutics are up 15% to $105.39 in morning trading.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use